Gainers
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) shares jumped 153% to $3.24 after the company announced the launch of PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
Civeo (NYSE: CVEO) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.61) by 47.54 percent. This is a 255.17 percent decrease over earnings of $0.58 per share from the same period last year.
Pulled from Benzinga Pro data, Civeo (NYSE:CVEO) posted Q3 earnings of $6.26 million, an increase from Q2 of 38.78%. Sales dropped to $184.23 million, a 0.39% decrease between quarters.
Civeo (NYSE:CVEO) reported its Q3 earnings results on Friday, October 28, 2022 at 06:30 AM.
Here's what investors need to know about the announcement.
Earnings
Civeo beat estimated earnings by 39.13%, reporting an EPS of $0.32 versus an estimate of $0.23.
Civeo (NYSE:CVEO) is set to give its latest quarterly earnings report on Friday, 2022-10-28. Here's what investors need to know before the announcement.
Analysts estimate that Civeo will report an earnings per share (EPS) of $0.23.
Civeo Corporation (NYSE: CVEO) recently announced that it was awarded a five-year contract from Oz Minerals Limited ("Oz Minerals") to provide facilities management services to Oz Mineral's Prominent Hill Village effective July 1, 2022. The contract includes an option to extend the agreement by up to two years.